

## Author's Accepted Manuscript

Elevated Serum Vascular Endothelial Growth Factor and Development of Cardiac Allograft Vasculopathy in Children

Kae Watanabe, Anis Karimpour-Fard, Alix Michael, Shelley D. Miyamoto, Stephanie J. Nakano



[www.elsevier.com/locate/bios](http://www.elsevier.com/locate/bios)

PII: S1053-2498(18)31462-1  
DOI: <https://doi.org/10.1016/j.healun.2018.04.015>  
Reference: HEALUN6752

To appear in: *Journal of Heart and Lung Transplantation*

Cite this article as: Kae Watanabe, Anis Karimpour-Fard, Alix Michael, Shelley D. Miyamoto and Stephanie J. Nakano, Elevated Serum Vascular Endothelial Growth Factor and Development of Cardiac Allograft Vasculopathy in Children, *Journal of Heart and Lung Transplantation*, doi:10.1016/j.healun.2018.04.015

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Elevated Serum Vascular Endothelial Growth Factor and Development of Cardiac Allograft Vasculopathy in Children

Kae Watanabe, MD<sup>1</sup>, Anis Karimpour-Fard, PhD<sup>2</sup>, Alix Michael, BS<sup>1</sup>, Shelley D. Miyamoto, MD<sup>1</sup>, Stephanie J. Nakano, MD<sup>1\*</sup>

<sup>1</sup>Division of Cardiology, Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado, USA.

<sup>2</sup>Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado, USA.

**\*Address correspondence and reprint requests to:** Stephanie Nakano, MD, Children's Hospital Colorado, 13123 E. 16<sup>th</sup> Ave. B-100, Aurora, CO 80045, stephanie.nakano@childrenscolorado.org. (720) 777-3218, Fax: (720) 777-7892

## Introduction

Cardiac allograft vasculopathy (CAV) is a leading cause of re-transplantation and death in pediatric heart transplant recipients<sup>1</sup>. CAV is a complex process involving alloimmune response, chronic inflammation, and smooth muscle cell proliferation, exemplifying cross talk between cytokines and growth factors<sup>2</sup>. The diagnosis of CAV is challenging: early in the development of CAV, patients are almost universally asymptomatic. Thus, despite the invasive nature, coronary angiography is performed on a routine schedule for CAV surveillance. Nevertheless, coronary angiography is not a highly sensitive method for detecting early CAV<sup>3</sup> since pathologic vascular remodeling is present before the diameter of the coronary artery lumen visibly decreases<sup>4</sup>. The use of intravascular ultrasound (IVUS) has evolved as a valuable adjunct to coronary angiography<sup>5</sup>, however cardiac catheterization is still required and its use is limited by expertise and patient size in the pediatric population. Once CAV is diagnosed, modification of immunosuppression to include proliferation signal inhibitors may slow the progression of CAV<sup>6</sup>, but no medical treatments are currently proven to reverse CAV. While the diagnosis of moderate or severe CAV portends a significantly higher risk of graft loss<sup>7</sup>, outcomes of pediatric patients with angiographically mild CAV are variable: graft survival is similar to those without CAV (stable mild CAV) but in a subset of patients, mild CAV can be rapidly progressive, necessitating listing for re-transplantation<sup>7-9</sup>. Elevated

Download English Version:

<https://daneshyari.com/en/article/8957262>

Download Persian Version:

<https://daneshyari.com/article/8957262>

[Daneshyari.com](https://daneshyari.com)